A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.

Last updated:
2026-08-01
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A FIRST-IN-HUMAN, MULTI-CENTER, RANDOMIZED, PARTICIPANT- AND INVESTIGATOR-BLINDED, PLACEBO CONTROLLED, SINGLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF EDK060 IN ADULTS WITH CHARCOT-MARIE TOOTH TYPE 1A (CMT1A)

Intervention/treatment:
EDK060
Medical condition:
CHARCOT-MARIE-TOOTH DISEASE TYPE 1A
Protocol code:
CEDK060A12101
Control number:
298575
Status:
Recruiting
Approved:
July 25, 2025
Trial phase:
Phase 1
For more information:
ClinicalTrials.gov - NCT07140614
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 60 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Novartis Pharmaceuticals
Role
CONTACT
Phone:
1-888-669-6682
Name
Novartis Pharmaceuticals
Role
CONTACT
Phone:
+41613241111
Sponsor
NOVARTIS PHARMACEUTICALS CANADA INC

Locations

Ontario

The Ottawa Hospital
Ottawa, Ontario, K1H 8L6
Recruiting
Name
Jessica Belanger
Role
CONTACT
Phone:
613-798-5555
Extension 19627
Name
Alberto Aleman
Role
PRINCIPAL_INVESTIGATOR

Quebec

CIUSS de l´Estrie-CHUS- Hôpital Fleurimont
Sherbrooke, Quebec, J1H 5N4
Recruiting
Name
Caroline Cayer
Role
CONTACT
Phone:
1-819-346-1110
Extension 13920
Name
Marie-France Rioux
Role
PRINCIPAL_INVESTIGATOR
Montreal Neurological Institute
Montreal, Quebec, H3A 2B4
Recruiting
Name
Julien Kridelka
Role
CONTACT
Phone:
514 398 78 58
Extension 13920
Name
Rami Massie
Role
PRINCIPAL_INVESTIGATOR
Novartis Investigative Site
Montreal, Quebec, H2X 1R9
Recruiting
Name
Julien Kridelka
Role
CONTACT
Phone:
514 398 78 58
Name
Rami Massie
Role
PRINCIPAL_INVESTIGATOR
Did you find what you were looking for?